Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors

Core Viewpoint - Jasper Therapeutics, Inc. is facing a class action lawsuit for investors who purchased securities during the specified class period, following a significant drop in stock price due to issues in a clinical trial [1][3]. Group 1: Class Action Details - The Portnoy Law Firm is advising Jasper investors of a class action on behalf of those who bought securities between November 30, 2023, and July 3, 2025 [1]. - Investors have until November 18, 2025, to file a lead plaintiff motion [1]. Group 2: Stock Price Impact - Following the announcement of issues related to a drug product lot in a clinical trial, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share on July 7, 2025 [3]. Group 3: Clinical Trial Update - On July 7, 2025, Jasper released updated data from its BEACON Phase 1b/2a study, indicating that results from certain dose cohorts were confounded by issues with one drug product lot [3]. - The company is currently investigating the drug product lot and expects to have results in the coming weeks [3]. Group 4: Legal Representation - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].